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Abstract: Glioblastoma (GBM) causes poor survival in patients even with aggressive treatment. 
Temozolomide (TMZ) is the standard chemotherapeutic choice for GBM treatment but resistance 
always ensues. Protein kinase CK2 (CK2) contributes to tumour development and proliferation in 
cancer, and it is overexpressed in human GBM. Accordingly, targeting CK2 in GBM may benefit 
patients. Our goal has been to evaluate whether CK2 inhibitors (iCK2s) could increase survival in 
an immunocompetent preclinical GBM model. Cultured GL261 cells were treated with different 
iCK2s including CX-4945, and target effects evaluated in vitro. CX-4945 was found to decrease CK2 
activity and Akt(S129) phosphorylation in GL261 cells. Longitudinal in vivo studies with CX-4945 
alone or in combination with TMZ were performed in tumour-bearing mice. Increase in survival  
(p < 0.05) was found with combined CX-4945 and TMZ metronomic treatment (54.7 ± 11.9 days,  
n = 6) when compared to individual metronomic treatments (CX-4945: 24.5 ± 2.0 and  
TMZ: 38.7 ± 2.7, n = 6) and controls (22.5 ± 1.2, n = 6). Despite this, CX-4945 did not improve mice 
outcome when administered on every/alternate days, either alone or in combination with 3-cycle 
TMZ. The highest survival rate was obtained with the metronomic combined TMZ+CX-4945 every 
6 days, pointing to the participation of the immune system or other ancillary mechanism in therapy 
response. 
Key words: Glioma; preclinical brain tumour; GBM therapeutic target; CK2 inhibitors; CX-4945; 
metronomic therapy; immune system 
 
1. Introduction 
Glioblastoma (GBM) is the most common aggressive glial primary brain tumour with an 
average survival of 14–15 months, even after aggressive treatment [1,2]. Temozolomide (TMZ) plus 
radiotherapy is the standard therapeutic choice for GBM treatment and, at present, produces the 
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best survival rates [3]. TMZ is an alkylating agent with a mechanism of action based in damaging 
DNA through methylation of guanine residues, finally leading to cell death. Methylation of the O6 
of guanine (O6-MeG) accounts for only about 5%–10% of DNA adducts, but is the primary 
responsible for the cytotoxic effects of TMZ. The O6-MeG lesion leads to DNA double-strand breaks 
(DSBs) and subsequent cell death via apoptosis and/or autophagy [4]. In our group, GL261 GBM 
tumour-bearing mice treated with TMZ showed a survival rate of 33.8 ± 8.7 days [5] versus control 
mice, 20.0 ± 4.1 days. Unfortunately, cancer stem cells (CSCs) are known to mediate chemoresistance, 
indicating GBM CSCs persistence even after standard treatment [6]. In addition, cellular exposure to 
DNA damaging agents (such as TMZ) may cause mutations and clastogenic effects, potentially 
resulting in additional malignant transformation [7]. Due to the poor outcome and resistance to 
standard therapy, efficient alternative non-mutagenic treatments are urgently needed for these 
tumours. 
Inhibition of protein kinases has become a standard of modern clinical oncology, and it could 
improve GBM patients’ survival. Protein kinase CK2 (CK2), an oncogenic protein kinase, contributes 
to tumour development, proliferation, and apoptosis suppression in cancer [8]. It is a constitutively 
active serine-threonine kinase and elevated CK2 expression levels have been demonstrated in 
several cancer types in comparison with normal tissue [9–11]. Its overexpression has been also 
proved in human GBM biopsies compared to adjacent normal tissue [12], regulating signalling 
pathways involved in tumour cell survival, proliferation, migration and invasion [13]. Furthermore, 
we have demonstrated that CK2 catalytic subunit (CK2α) expression level was higher in preclinical 
GL261 GBM tumour and in contralateral brain parenchyma than in wild type C57BL/6 brain 
parenchyma [14]. These characteristics identify CK2 as an active therapeutic target, and targeting 
CK2 in GBM treatment could benefit patients.  
Different CK2 inhibitors (iCK2) have been studied for cancer applications, such as  
4,5,6,7-tetrabromobenzotriazole (TBB) [15,16] or apigenin (APG) [17,18]. Additionally, a more 
specific CK2 inhibitor, 5-(3-chlorophenylamino)benzo[c][2,6] naphthyridine-8-carboxylic acid 
(CX-4945) [19–23] has been reported as the first CK2 inhibitor in clinical stage [24,25]. In vitro studies 
of breast cancer [21] and studies with an intracranial xenograft murine glioma model [23] have also 
presented successful results for CX-4945. In addition, it has been reported that CX-4945 decreases 
GBM initiating cell growth and stemness through β-catenin [26]. Moreover, other promising CK2 
inhibitors are in development, such as tetrabromo-deoxyribofuranosyl-benzimidazole (TDB), a dual 
inhibitor of CK2 and proviral integration of Moloney virus (PIM-1) [27]. These results highlight the 
relevance of CK2 and its interwoven signalling targets in tumour growth and progression. 
Moreover, new therapeutic schedules are being investigated using chemotherapeutic drugs in a 
metronomic-like approach, referring to administrations of low and equally spaced doses of 
chemotherapeutics without long rest periods in between [28,29], to try to activate immune responses 
to potentiate tumour regression and avoid regrowth [29]. For instance, cyclophosphamide (CPA) 
metronomic therapy has been shown to activate antitumour CD8+ T-cell response, and also induce 
specific long-term T-cell tumour memory in GL261 GBM tumours growing subcutaneously in 
immunocompetent mice [30].  
The use of animal models in tumour research is mandatory in the search for new therapeutic 
targets due to obvious ethical restrictions related to human patients. One of the most investigated 
immunocompetent murine brain tumour models is GL261 growing into C57BL/6 mice, used for 
more than 20 years in different therapy evaluation approaches [5,31,32]. 
In this work, we have evaluated iCK2 effects over cultured GL261 cells viability to select the 
best candidates for in vivo preclinical studies. Also, preliminary in vivo work with preclinical GBM 
was performed, regarding maximum tolerated doses (MTD), tumour targeting effects assessment 
and survival rate evaluation in longitudinal studies with C57BL/6 mice bearing GL261 tumours 
treated with iCK2.   
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2. Results 
2.1. GL261 Cell Viability under CK2 Inhibition Treatment 
Cultured GL261 cells sensitivity to different treatments was assessed. Figures 1A,B showed a 
low half maximal effective concentration (EC50) (12.9 ± 2.3 µM) for APG, similar to CX-4945  
(16.5 ± 5.5 µM), but the final viability reached with APG was only up to 40% of the initial value. 
Instead, TBB and CX-4945 both decreased viability to about 20% of the initial value. Regarding to 
TBB, a concentration of 91.4 ± 8.3 µM produced a 50% viability decrease, whereas for CX-4945, a 
concentration of 16.5 ± 5.5 µM produced the same results. In the case of TDB, it showed the lowest 
EC50 (8.1 ± 1.5 µM), and the final viability obtained was similar to CX-4945. TMZ EC50 was 747.6 ± 
63.3 µM.  
 
Figure 1. GL261 cells viability after treatment; (A) GL261 cells viability (%) “XTT assay” after 72 h of 
treatment with temozolomide (TMZ): 0 µM, 0.8 µM, 4 µM, 20 µM, 100 µM, 200 µM, 500 µM, 1000 
µM, 5000 µM and 10,000 µM, apigenin (APG) and tetrabromobenzotriazole (TBB): 0 µM, 0.8 µM, 4 
µM, 20 µM, 100 µM, 200 µM and 500 µM, CX-4945 and 
tetrabromo-deoxyribofuranosyl-benzimidazole (TDB): 0 µM, 0.2 µM, 2 µM, 5 µM, 20 µM, 50 µM, 100 
µM, 200 µM and 500 µM); 100% cell viability was assigned to control cells treated with 0.8% 
dimethyl sulfoxide (DMSO) (v/v). Experiments were performed with n = 3–9, and mean ± SD values 
are shown; (B) EC50 (Half maximal, 50% viability decrease, effective concentration) mean ± SD values 
obtained with the different treatments to GL261 cells after 72 h of incubation with the drug; (C) 
Boxplot of GL261 cells viability after TMZ and CX-4945 treatment. GL261 cells viability (%) “MTT 
assay” after 72 h of treatment. On the left side, control (n = 4), CX-4945 30 µM (n = 4), TMZ 1 mM (n = 
4) and CX-4945 30 µM plus TMZ 1 mM (n = 3); on the right side, control (n = 4), CX-4945 50 µM (n = 4), 
TMZ 1.5 mM (n = 4) and CX-4945 50 µM and TMZ 1.5 mM (n = 3); 100% cell viability was assigned to 
control cells treated with 0.8% DMSO (v/v). As both experiments were performed at the same time, 
controls were acquired only once and, accordingly, the same control cells results are shown for both 
experimental conditions. Experiments were performed with n = 3–4, and mean ± SD values are 
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shown. Boxplot (the limits of the box represent quartiles 1 (Q1) and 3 (Q3) of the distribution, the 
central line corresponds to the median (quartile 2). The whiskers symbolize the maximum and 
minimum values in each distribution.  
Additionally, an in vitro experiment with combined treatment of GL261 cells was outlined, and 
as it can be seen in Figure 1C, we could demonstrate that the combined administration of CX-4945 
and TMZ to GL261 cultured cells presented an increased efficacy in comparison with treatments of 
single substances alone. TMZ alone reduced cell viability to 82.8% ± 5.6% (at 1 mM) and 59.2% ± 3.2% 
(at 1.5 mM) in comparison to controls, whereas CX-4945 alone reduced cell viability to 52.0% ± 1.4% 
(at 30 µM) and 31.9% ± 2.1% (at 50 µM). The combined administration of both therapeutic agents 
resulted in a cell viability reduction to 35.6% ± 4.7% (TMZ 1 mM + CX-4945 30 µM ), and to  
21.5% ± 1.0% (TMZ 1.5 mM + CX-4945 50 µM) in comparison to controls, being clearly superior to the 
efficacy of each substance separately. Concentrations chosen were above the EC50 (Figures 1A,B), to 
ensure enough cell viability reduction. In the remainder of this study, we decided to focus first on 
CX-4945, one of the two most effective CK2 inhibitors tested on GL261 cell viability (Figure 1) 
because unlike the other one, TDB, it has been already used in clinical trials [24,25]. 
2.2. CK2 Activity in GL261 Cells Treated with CX-4945 
CK2 activity was analysed in GL261 cells treated with CX-4945 and in control, non-treated cells. 
As a reporter of endocellular CK2 activity, the phosphorylation state of the well-known CK2 target 
Akt (S129) [333] was analysed. In Figure 2A, p-Akt (S129) normalized to total Akt1 expression was 
obtained (at 8 h and 24 h post-treatment) and CX-4945 presented a dose-scale response, being p-Akt 
(S129) lower when higher concentrations of the inhibitor were applied. In addition, Figure 2B,C 
shows that p-Akt (S129), normalized to total Akt1, is significantly (p < 0.05) less phosphorylated in 
GL261 cells treated with 67.2 µM CX-4945 compared to control cells. No differences were found for 
CK2α and CK2β expression (p > 0.05) between treated and non-treated cells. CK2 activity was also 
measured in cell lysates, exploiting a highly specific peptide substrate [34] and significant 
differences (p < 0.05) were found between CX-4945 treated cells (Figure 2D) and control cells 
(pre-treatment). These results indicate that CX-4945 reduces endogenous CK2 activity when used to 
treat cultured GL261 cells, but not the total amount of CK2 subunits present in those cells.  
2.3. CX-4945 Mice Tolerability  
Before starting longitudinal in vivo treatment experiments, tolerability evaluation was 
performed for CX-4945 and TMZ. As it can be observed in Figure S1A, in the first phase, an MTD of 
920 mg/kg was estimated for TMZ and of 1200 mg/kg for CX-4945. These MTD values were chosen 
because the doses of 1840 mg/kg (TMZ) and 2400 mg/kg (CX-4945) produced toxicity/adverse effects 
to the treated mice. In phase 2, when n = 3 mice where administered with a dosage of 920 mg/kg of 
TMZ, 9 days after this single TMZ administration, noticeable body weight decrease was detected in 
all mice. For this reason, the experiment was repeated with an n = 3 at the next lower dose, 480 mg/kg 
(Figure S1B). A similar situation was observed for CX-4945 when 1200 mg/kg of CX-4945 were 
administered per n = 3, one mouse was found dead, the day after administration so the experiment 
was repeated at 600 mg/kg (Figure S1C). These results indicate that the MTD (acute dose) is 480 
mg/kg for TMZ and 600 mg/Kg for CX-4945, under our experimental conditions.  
2.4. CK2 Activity in CX-4945 Treated Mice 
In preliminary in vivo target validation studies, CK2 activity was found significantly (p < 0.05) 
reduced in all samples analysed, in comparison to controls (Figure 2E). Values obtained at the 
different time points (2 h, 6 h and 24 h) did not present significant differences when compared  
(p > 0.05), and results were grouped in n = 6 treated and n = 6 control mice. These results indicate that 
CX-4945 successfully reached tumours and exerted the expected effect on its target. 
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Figure 2. CK2 activity in GL261 cells and tumour samples. (A) Western blot for GL261 cell protein 
extracts (25 µg) treated with increasing doses of CX-4945 (from left to right: control (C) and CX-4945 
treated cells 5 µM, 10 µM, 20 µM, 30 µM and 60 µM). This experiment was performed with n = 1 for 
each condition and for 8 h (upper part) or 24 h (lower part). p-Akt(S129), Akt1 total and β-Tubulin 
proteins were analysed; (B) Western blot for GL261 cell protein extracts (25 µg) treated with 67.2 µM 
CX-4945 (from left to right: control (C) and CX-4945 treated cells for 1 h, 4 h, 8 h, 12 h and 24 h). The 
experiment was performed with n = 3 for each condition. p-Akt(S129), Akt1 total, CK2α, CK2β and 
β-Actin proteins were analysed; (C) Quantification of western blot (WB) for GL261 cell protein 
extracts (25 µg) treated with CX-4945 (n = 3 per each condition). Ratio (%) of p-Akt(S129) content 
divided by Akt1 total content, while the control values (C) for this ratio are taken as the 100% start 
value. * = p < 0.05 for Student’s t-test for the comparison of control and treated groups; (D) CK2 
activity measured on a CK2-specific synthetic peptide in lysates from GL261 cells treated with 67.2 
µM CX-4945 (n = 3 for each condition). Treatment during 1 h, 4 h, 8 h, 12 h and 24 h. * = p < 0.05 for 
Student’s t-test for the comparison of control (100% initial value) and treated groups; (E) Boxplot of 
CK2 activity in CX-4945 treated mice compared to control mice. CX-4945 was administered to treated 
mice during 3 days (a total of 150 mg/Kg/day split into two administrations per day) and mice were 
euthanized 2 h, 6 h and 24 h after the last CX-4945 administration. As no CK2 activity differences (p > 
0.05) were detected between euthanization time points (2 h, 6 h and 24 h), they were grouped in a 
single CX-4945 treated group. (* = p > 0.05 for Student’s t-test for the comparison of control and 
treated groups). CK2 activity was measured on tissue homogenates by means of radioactive assays 
towards a CK2-specific peptide. Boxplot features as in Figure 1 legend. 
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2.5. Metronomic Longitudinal Treatments with CX-4945 and/or TMZ in Tumour-Bearing Mice 
Three metronomic (every 6 days) administration treatments were performed: CX-4945 (n = 6), 
TMZ (n = 6) and a combination of CX-4945 and TMZ (n = 6), Figure 3. For the CX-4945 metronomic 
treatment, a survival rate of 24.5 ± 2.0 days was found, whereas for TMZ treatment, the survival rate 
was 38.7 ± 2.7. For the combined TMZ and CX-metronomic treatment, a provisional survival rate 
(right censored data) of 54.7 ± 11.9 days was found (three mice were still alive at day 65 p.i.). All 
groups offered significantly higher survival rate (p < 0.05) compared to control mice group (22.5 ± 1.2 
days), Figure 3A. Besides, TMZ alone produced better survival than CX-4945 alone, while combined 
TMZ and CX-4945 was better than any of the two alone. Moreover, tumour volume evolution 
(Figure 3B–E) was significantly different (p < 0.05) when comparing treated groups with control 
group. Body weight was also inspected every day (Figure S3D). At the time of comparing the 
different treated groups, significant differences were found regarding weight, tumour volume 
evolution and survival rate, being the best results always obtained with the metronomic treatment 
combining TMZ with CX-4945. 
 
Figure 3. Tumour volumes and survival rates for 6-day metronomic treatment. (A) Survival  
Kaplan-Meier curve for metronomic CX-4945 treated mice (n = 6), blue line, metronomic TMZ treated 
mice (n = 6), red line, CX-4945 and TMZ metronomic treated mice (n = 6), green line, and control mice 
(n = 6), black line. Significant differences (p < 0.05) were observed between all treatment groups 
analysed in comparison with control mice; (B) Tumour volumes of control mice (n = 6); (C) Tumour 
volumes of metronomic CX-treated mice (n = 6); (D) Tumour volumes of metronomic TMZ-treated 
mice (n = 6); (E) Tumour volumes of metronomic CX and TMZ- treated mice (n = 6). Significant 
differences were found between groups (p < 0.05) when comparing control mice with treated mice, 
and when comparing different treatments between them (TMZ, CX-4945 and combined TMZ and 
CX-4945). The dashed lines indicate therapy administration points. Cxxxx corresponds to a unique 
alpha-numeric animal identifier code in the GABRMN group.  
  
Pharmaceuticals 2017, 10, 24 7 of 18 
 
2.6. Non-Metronomic Longitudinal Treatments with CX-4945 and/or TMZ in Tumour-Bearing Mice 
Despite having demonstrated that CX-4945 produces a better effect in GL261 implanted mice 
when administered in combination with TMZ and administered every 6 days, additional results of 
longitudinal mice experiments must be taken into account to better understand its causes, as in some 
cases, antagonistic effects can be observed. 
 
Figure 4. Tumour volumes, survival rates and CK2 activity and expression in CX-4945 treated mice. 
Tumour volumes (recorded at days 5, 11 and 16 p.i.) of treated (n = 6, black line) and control  
non-treated bearing tumour mice (n = 6, red line) for (A) CX-4945 treated every day GL261 implanted 
mice and (B) CX-4945 treated alternated days GL261 implanted mice. No significant differences were 
observed between groups (p > 0.05). The dashed blue line indicates the CX-4945 therapy start point; 
(C) Survival Kaplan-Meier curve for CX-4945 treated every day mice (n = 6) and control mice (n = 6); 
(D) Survival Kaplan-Meier curve for CX-4945 treated alternated days mice (n = 6) and control mice (n 
= 6). No significant differences were found between groups (p > 0.05). The dashed blue line indicates 
the CX-4945 therapy start point; (E) Tumour CK2 activity (%) in mice treated with CX-4945, n = 3, 
compared with control mice, n = 3. (* = p < 0.05 for Student’s t-test for the comparison of control and 
treated groups); (F) Western blot for tumour total protein homogenate (40 µg) from different mice 
treated with CX-4945, n = 3, compared with control mice, n = 3. p-Akt(S129), Akt1 total, CK2α, and  
α-tubulin proteins were analyzed; (G) Quantification of Western blot for tumour total protein 
homogenate (40 µg) from mice treated with CX-4945, n = 3, compared with control mice, n = 3. Ratio 
(%) of p-Akt (S129) content divided by Akt1 total content. * = p < 0.05 for Student’s t-test for the 
comparison of control and treated groups.  
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In this respect, CX-4945 treatment (either every day or alternated days administration at the 
classical dose/schedule described by others [21-23]) was performed in GL261 tumour-bearing mice, 
and no improvement was detected regarding tumour evolution (Figures 4A,B) or survival rate  
(p > 0.05, Figures 4C,D) in comparison with control mice. Figures 4C,D show the survival rate for 
every day CX-4945 treatment (20.5 ± 2.0 vs. 20.0 ± 2.1 days for control mice) and for alternated days 
CX-4945 treatment (20.5 ± 1.8 days vs. 20.5 ± 1.6 days for control mice). Body weight was inspected 
every day and no significant differences (p > 0.05) were observed between groups (Figure S3A). 
Examples of T2w images for CX-4945 treated mice are shown in Figure S4. To ensure that CX-4945 
reached the tumour, even when no effect on survival could be detected, 6 arbitrarily chosen tumour 
samples from the CX-4945 treatment every day (n = 3 treated, n = 3 controls) were analysed for CK2 
activity and p-Akt (S129) WB. The CK2 activity was more than seventeen-fold reduced in CX-4945 
treated tumour compared to control tumour after 10.0 ± 2.0 days of treatment (Figure 4E) and p-Akt 
(S129)/Akt1 ratio (Figures 4F,G) was found around 20% reduced in CX-4945 treated mice, indicating 
that CX-4945 had reached the desired target and inhibited CK2 activity, despite no increase of the 
survival rate was observed. 
An additional experiment with three cycles TMZ and CX-4945 combined administered every 
day, produced significantly worse results than TMZ treatment alone (see [5] and Figure S5). In other 
words, CX-4945 treatment in vivo, in these conditions, seems to inhibit the beneficial effect produced 
by TMZ. Tumour volume curves are shown in Figure 5A. As stated in Figure S3B, three out of the six 
treated mice died around day 16 p.i., without noticeable weight reduction. Control mice weight 
evolution can be observed in Figure S3C. To compare survival rates between groups, Kaplan-Meier 
survival curves were elaborated, and no significant differences were found between TMZ  
3 cycles + CX-4945 every day treated group and control group (p > 0.05, Figure 5B). The average 
survival rate was 21.3 ± 9.0 days for treated mice (TMZ 3 cycles + CX-4945 every day) vs. 19.8 ± 1.5 
days for control mice, while for TMZ three cycles only treated mice from previous work (Figure S5) 
average survival time found was 33.9 ± 11.7 days. In addition, no significant differences were found 
when comparing TMZ 3 cycles+CX-4945 every day and CX-4945 everyday alone (survival rates of 
19.8 ± 1.5 vs. 20.5 ± 2.0 days, respectively). C984 mouse was proven to be an outlier both in Grubbs’ 
and Dixon’s tests for single outliers (survival rate of 39 days, p < 0.05), but still it was maintained for 
survival analysis calculations. Overall average survival for control (untreated) GL261 harbouring 
mice was 20.8 ± 1.8 days, n = 18, while previous work from our group had obtained 21.5 ± 3.7 days,  
n = 61 (Figure S5), without significant difference (p > 0.05) with the present cohort of mice. 
 
Figure 5. Tumour volume and Kaplan-Meier survival curve of mice treated with TMZ combined 
with CX-4945; (A) Tumour volumes (recorded at days 6, 11, 14, 17, 19 and 21 p.i.) of control GL261 
implanted mice (n = 6, blue line) and combined TMZ-CX-4945 cycles in GL261 implanted mice (n = 5, 
red line). The dashed blue line indicates TMZ and CX-4945 therapy start point. No significant 
differences were observed between groups for comparisons of control and treated mice tumour 
volumes at each time point (p > 0.05). C984 has been excluded from tumour volume comparisons 
because it has been proven an outlier with Grubb’s and Dixon’s tests; (B) Survival Kaplan-Meier 
curves for TMZ and CX-4945 treated mice (n = 6) and control mice (n = 6). No significant differences 
were found between groups (p > 0.05). The dashed blue line indicates TMZ and CX-4945 therapy start 
point.  
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3. Discussion 
3.1. Effect of iCK2 on GL261 Cultured Cells 
GL261 cultured cells sensitivity was variable for the different iCK2 evaluated. CX-4945 
decreased cell viability to about 20% of the control value. The EC50 found for CX-4945 (16.5 ± 5.5 µM) 
is similar to the EC50 found in breast cancer cell lines by others [21], who reported values between 1.7 
and 20 µM. The lowest EC50 (8.1 ± 1.5) was found for TDB, concurring with a previous study [27], 
where a half maximal cell death concentration (DC50) of 2.45 ± 0.84 µM was observed for the human 
HeLa cell line and of 3.45 ± 0.2 µM for human T lymphoblastoid cells. The standard GBM 
chemotherapeutic agent, TMZ, reached the EC50 at 747.6 ± 63.3 µM, which agrees with high values of 
half maximal inhibitory concentration (IC50) found by others [35]. 
In addition, the combined TMZ and CX-4945 treatment carried out with GL261 cells in vitro 
presented increased efficacy regarding cell viability reduction, in comparison with both therapeutic 
agents administered separately (Figure 1C). The low EC50 of CX-4945 and TDB, combined with a 
significant decrease in cell viability, indicated that they should be suitable for future preclinical 
evaluation with GL261 tumours in vivo. CX-4945 was eventually chosen because it has been already 
described in clinical and preclinical studies [24,25]. 
As expected, we observed a significant reduction of CK2 activity in CX-4945 treated GL261 cells 
(Figure 2D). This was accompanied by the decrease of the phosphorylation of the CK2 target Akt 
(S129) (Figure 2B,C), similarly to [22] in prostate PC3 cancer cells. In addition, the Akt 
phosphorylation was found reduced as the CX-4945 concentration was increased, in a  
dose-dependent manner (Figure 2A). It has been described that the antiapoptotic effect of CK2 can 
be partially mediated by upregulation of the Akt/PKB pathway [33], thus the reduced viability 
found in GL261 cultured cells treated with CX-4945 can be also related to the down-regulation of this 
pathway, although the involvement of other pathways could also have an effect in the overall results 
observed [36]. These results reinforced the idea that CX-4945 could be a promising candidate for 
non-mutagenic brain tumour therapy in our preclinical GBM model.  
3.2. Effects of CX-4945 in In Vivo Studies 
In in vivo studies, CX-4945 was described to inhibit the activation of STAT-3, NF-κB p65 and 
Akt, in nude mice with intracranial human GBM X1046 xenografts [23]. In our work, we could 
demonstrate that 3 days of CX-4945 administration to GL261 tumour-bearing mice caused a decrease 
in CK2 activity of tumour samples analysed to 35% of control values (Figure 2E). This confirms that 
CX-4945 reached the target organ and caused the expected effect, as also reported in [23], although 
no further detailed study of the affected pathway was performed in our case. Regarding CX-4945 
pharmacokinetics, described extensively elsewhere [37], it has a long half-life (more than 5 h) and 
high oral bioavailability (20%) in mice, without detectable mutagenicity, genotoxicity or cardiac 
toxicity. The results described in our work agree with this, showing that CX-4945 was well tolerated 
in mice as assessed by minimal changes in body weight during the course of treatment compared to 
control vehicle (Figure S3A). 
3.3. Non-Metronomic CX-4945 Longitudinal In Vivo Studies 
Although in vitro results indicated that CX-4945 should be a promising candidate for preclinical 
GBM therapy, unexpectedly, the non-metronomic in vivo treatment of GL261 tumour-bearing mice 
did not produce a better outcome. No tumour growth arrest and no survival improvement were 
detected (Figures 4A-D). This is in contrast to a previous in vivo study [23] with intracranial human 
xenografts treated with CX-4945 which showed significant effects in mice survival (50.2–67.8 days 
for treated mice, versus 35.6–40.4 days for control mice). However, there are relevant differences 
between work reported in [23] and our work, which could explain, at least partially, the differences 
observed. In [23], athymic nude mice were used, while in our experiment, immunocompetent 
C57BL/6 mice have been used, because we consider that they mimic better the clinical patient 
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situation. Moreover, despite authors in [23] inoculated more cells for tumour generation (5 × 105 cells 
vs. 105 cells, in our study), their tumour growth pattern was much slower (survival rate for their 
control mice, 35.6–40.4 days, whereas our control mice survived 17–21 days). In this sense, it is 
widely accepted that small, slow-growing tumours are easier to treat than established, fast-growing 
tumour [38,39]. 
It is also worth mentioning that longitudinal in vivo studies reported by other authors did not 
present satisfactory results with CX-4945 alone in the same doses used in this work, although they 
studied other tumour types [36]. In this sense, using a drug combination for therapy involving  
CX-4945 was already suggested by authors in [36,40], with an additive effect recorded, which is also 
in line with our decision to study a drug combination (CX-4945 and TMZ) in order to perhaps 
improve the therapy response results produced by CX-4945 alone.  
3.4. Non-Metronomic Combined CX-4945 and TMZ Longitudinal In Vivo Studies 
Thus, the unexpected result obtained with the in vivo longitudinal study using CX-4945 alone 
in GL261 tumour-bearing mice lead us to hypothesize that a combined therapy with CX-4945 
superimposed with TMZ could produce better results. The TMZ treatment in preclinical GBM mice has been 
proved useful in our group [5] with an average survival of 33.9 ± 11.7 days for treated animals (see 
also Figure S5), significantly higher than control mice (21.5 ± 3.7 days). TMZ cytotoxicity is 
predominantly mediated by O6-methylguanine (O6-MG) DNA lesions, which are repaired by the 
DNA repair protein O(6)-methylguanine-DNA methyltransferase (MGMT) [41]. Consequently, 
GBM patients whose tumours express low MGMT level, due to promoter hypermethylation, are 
more responsive to TMZ based therapy [42,43]. Protein Kinase CK2 is a novel interaction partner of 
JAK1/2, potentiating janus kinase (JAK) and signal transducer and activator of transcription 
(STAT-3) activation [44]. A CK2 inhibitor could reduce STAT-3, which has been implicated in the 
resistance of GBM to TMZ, downregulating MGMT and diminishing TMZ resistance [45], 
highlighting the potential of use of iCK2 combined with standards of care like TMZ. Nevertheless, 
the combined treatment (standard 3-cycle TMZ described by our group [5] superimposed with 
non-metronomic schedule for CX-4945) did not produce the expected improvement, except by case 
C984, classified as an outlier (Figure S3C), which followed an evolution pattern similar to 
TMZ-treated cases described in [5]. Except for this case, the combined TMZ+CX-4945 therapy 
showed similar results than control mice (survival of 17.8 ± 2.8 days for treated mice vs. 19.8 ± 1.5 
days for control mice), reversing the beneficial effect of TMZ 3 cycles treatment. However, the 
combined TMZ and CX-4945 treatment carried out with GL261 cells in vitro presented increased 
efficacy regarding cell viability reduction, in comparison with both therapeutic agents administered 
separately (Figure 1C). This reinforced the idea that an increased efficacy, instead of an antagonistic 
effect, should have been observed in vivo with the combined therapy.  
One of the possible explanations for those results could be due to dramatic CX-4945 ‘off target’ 
effects, e.g., leading to strong splicing inhibition [46]. We cannot discard that these effects, rather 
than CK2 inhibition, are responsible for reversing TMZ efficacy. Another explanation could be 
related to the role of the immune system in therapy response [47] (see below), which would help to 
explain why a synergistic effect was observed with GL261 treated in vivo cells but it was not seen in 
our early non-metronomic in vivo approach.  
3.5. Metronomic CX-4945 and/or TMZ Longitudinal In Vivo Studies and Possible Implication of the Immune 
System 
The disappointing results obtained with non-metronomic administration schedules of CX-4945 
both alone or in combination with TMZ lead us to raise the hypothesis that a possible interference 
with the host immune system was taking place, and it was the cause of the unfavourable outcome. 
Thus, we decided to move to a metronomic approach to discard or confirm this hypothesis. The  
so-called “metronomic therapy” [28], referring to equally spaced, low doses of chemotherapeutic 
drugs without extended rest periods, has been studied by several groups in the preceding years. 
Also, new therapeutic regimens with conventional drugs have been evaluated in order to activate 
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immune responses that enhance tumour regression and prevent tumour regrowth. Recent studies 
with cyclophosphamide (CPA) metronomic therapy proved that this type of administration not only 
activates antitumour CD8+ T-cell response, but also induces long-term, specific T-cell tumour 
memory in GL261 tumours growing subcutaneously in immunocompetent mice [30,48]. These 
authors have also proven that a 6-day intermittent was the optimum timing for this therapy and this 
could agree with the 7-day cycle for immune cell recruitment described in [49], and accordingly this 
was the schedule chosen for our metronomic treatments. Indeed, the metronomic (every 6 days) 
therapy carried out in our study offered a better mice outcome, being the best results produced by 
CX-4945 and TMZ combined (54.7 ± 11.9 days) metronomic therapy, which was better than CX-4945 
or TMZ metronomic therapies alone. These results reinforce the idea of the role of the immune 
system in therapy response [47] in GBM, and could explain the variation in our results depending on 
the therapy administration protocol used. Regarding the immune system cycle involved in tumour 
response, we should consider that the cytotoxic T-lymphocytes (CTLs) have a relevant role in the 
defence against cancer recognizing antigens presented on the surface of transformed cells, following 
a complex cycle described in [50]. Also, the whole cycle for immune cell response could take around 
7 days in mouse brain [49], which is in agreement with the 6-day interleave that we have used in our 
work. It was also described the need of a functional CD5-dependent CK2 signalling for efficient 
differentiation of naive CD4+ T cells into Th2 and Th17 cells [50,51], involved in monocytes 
differentiation into dendritic cell subsets [52]. Moreover, authors in [53] have recently described 
impairment of Th17 cells development by CK2 inhibition with CX-4945 in a C57BL/6 mouse model 
of experimental autoimmune encephalomyelitis. Accordingly, CK2 inhibition (which could take 
place in every day or alternated days CX-4945 administration) could impair proper attraction of 
immune response triggered by immunogenic cell death signals. In this respect, several authors have 
described immunogenic death caused by TMZ therapy in GBM [54,55] and it could explain the 
reversal of beneficial effects observed in the non-metronomic combined therapy. Additionally, CK2 
inhibition in vitro has been shown to compromise normal T-cell viability of cultured peripheral 
blood T-lymphocytes harvested from chronic lymphocytic leukemia patients [56], while other 
authors [36] demonstrated cytotoxic effects of CX-4945 administration, alone, in head and neck 
cancer cultured cell lines and xenograft models. Further work will be needed to clarify, in vitro and 
in vivo, the extent of immunogenic cell death produced by TMZ and CX-4945, alone or in 
combination, in the GL261 GBM model. 
In summary, it is tempting to speculate that when CX-4945 is administered every day or in 
alternated days, it could cause an impairment of immune system elements needed for tumour 
response. Furthermore, when it is administered combined with TMZ (three cycles of therapy),  
CX-4945 reversed the beneficial effect of TMZ. When TMZ and CX-4945 are administered in a 
metronomic scheme every 6 days, the activation of the immune cell recruitment and response, which 
can take around 7 days [49], would not be significantly compromised. Accordingly, a word of 
caution should be said when treating immunocompetent preclinical tumours with CX-4945: the 
continued administration of a drug could impair the proper attraction of immune response 
contributing to therapeutic effects being evaluated.  
4. Materials and Methods 
4.1. GL261 Cells  
GL261 mouse glioma cells were obtained from the Tumour Bank Repository at the National 
Cancer Institute (Frederick, MD, USA) and were grown as previously described in [57].  
4.2. Cell Viability Assay 
GL261 cells were plated in 96-well multiwell plates (Sigma Aldrich, Madrid, Spain) and 
allowed to adhere for 24 h before adding drugs to the medium (TMZ, APG, TBB, CX-4945 and TDB). 
Controls included cell culture medium and 0.4%–0.8% range of dimethyl sulfoxide (DMSO). After 72 
h of drug exposure, cell viability was measured using XTT or MTT Assay (Sigma Aldrich). Half 
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maximal effective concentration (EC50) was calculated using GraphPad Prism software (version 5, 
[58] See Supplementary Material file for further details.  
4.3. Antibodies 
CK2α-subunit (dil. 1:1000) rabbit antiserum was raised against [376–391] region of human 
protein, corresponding to the specific C-terminal sequence. CK2β (Monoclonal, dil. 1:750, rabbit, Ref 
Ab76025) and Phospho-Akt (S129) (dil. 1:1000, rabbit, Ref 133458) were purchased from Abcam 
(Cambridge, UK). β-actin (dil.1:2000, mouse, Ref A2228) and α-tubulin (dil.1:2000, mouse, Ref A5441) 
were obtained from Sigma-Aldrich, and β-tubulin (dil. 1:1000, rabbit, Ref 2146) and Akt1 (dil 1:500, 
rabbit, Ref C3H10) were purchased from Cell Signalling Technology (Beverly, MA, USA). Secondary 
antibodies towards rabbit and mouse IgG (dil.1:2000), conjugated to horse radish peroxidase, were 
purchased from PerkinElmer (Waltham, MA, USA). 
4.4. Target Evaluation in GL261 Cultured Cells with CX-4945 Treatment 
For the CK2 expression and activity studies, a total of 18 flasks (75 cm2) of GL261 cells were 
cultured (n = 3 as controls, n = 3 as CX-4945 treatment during 1 h, 4 h, 8 h, 12 h and 24 h). Cells were 
cultured in flasks until 50% confluence and at that moment, CX-4945 was added to the “treatment” 
flasks, and an equal amount of the vehicle (DMSO) was added to the control cells. The CX-4945 
concentration used was 67.2 µM (four times the EC50, as stated by other authors [59]). Still, this 
concentration was included in the range of maximum CX-4945 effect as it can be seen in Figure 1. An 
in vitro dose-response study was also conducted in cultured GL261 cells in order to check for 
increasing target effects. For this, 300,000 cells/well were plated in 6-well plates and concentrations 
of CX-4945 of 0, 5, 10, 20, 30 and 60 µM were added. Treatments were performed during 8 and 24 h. 
Therapeutic agent preparations (CK2 inhibitors and TMZ) can be found in the Supplementary 
Materials file. 
4.5. Animal Model for In Vivo Studies 
A total of 60 C57BL/6 female wild type mice weighting 21.2 ± 1.3 g were used for this study. 
They were obtained from Charles River Laboratories (Charles River Laboratories International, 
L’Abresle, France) and housed in the animal facility of the Universitat Autònoma de Barcelona. All 
studies described in this paper were approved by the local ethics committee (Comissió d’Ètica en 
Experimentació Animal i Humana (CEEAH), [60]), according to the regional and state legislation 
(protocol DMAH-8236/CEEAH-2785). Tumours were induced in C57BL/6 mice by intracranial 
stereotactic injection of 105 GL261 cells with 4 µL of RPMI (Roswell Park Memorial Institute) 
medium in the caudate nucleus, as previously described by us [61]. Mice were weighted every day 
or at alternated days (for metronomic treatments) and tumour volumes were followed using 
T2-weighted MRI acquisition as in [5] the day 6 and 10-11 after implantation. Mice with most 
homogeneous weights and tumour sizes were chosen to make experimental groups after 
randomization (usually n = 6 per studied condition), and therapy started. The volume and weight 
averages did not show significant differences (p > 0.05) between the experimental groups  
(Tables S1–S4). 
4.6. CX-4945 and TMZ Tolerability Assay 
Two phases were performed for this study, based in the work described in [62]: in phase 1, n = 1 
was used and the starting TMZ dose was the one described by us (60 mg/kg/day) [5], and for  
CX-4945, the dose was the one described in [22,59] (150 mg/kg/day), as no adverse effects have been 
observed with these doses. Administrations were performed with an oral gavage. Doses were 
increased (Table S5) until detection of toxicity symptoms (Table S6). Once MTD was estimated in 
this first phase, a second phase took place and a group of n = 3 mice were administered with the 
calculated MTD. Mice follow-up (weight + welfare parameters for up to 30 days) was carried out 
every day (Figure S1).  
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4.7. Use of iCK2 in Tumour-Bearing Animals 
4.7.1. Preliminary Studies of Target Validation 
CX-4945 therapy was administered to tumour-bearing mice (n = 2) during three days (150 
mg/kg split into two administrations per day). CX-4945 vehicle, phosphate buffer 25 mM pH 7.2 was 
administered to control mice (n = 2 per each experimental time). Administrations were performed 
with an oral gavage. Mice were euthanized at 2 h, 6 h and 24 h after the last administration for both 
treated and control mice to assess CK2 activity compared to control mice. Tumour samples were 
stored in liquid nitrogen until further processing. 
4.7.2. Longitudinal Studies with iCK2 (alone or in combination) 
CX-4945 therapy was administered to tumour-bearing mice, every day or in alternated days, 
150 mg/Kg/day [23] (Figures S2A,B). CX-4945 total dose for every day or alternated days treatment 
administered was 150 mg/Kg/day, split into two times per day (75 mg/kg at 8 h, and 75 mg/kg at 16 
h) and dissolved in vehicle administration, which was phosphate buffer 25 mM pH 7.2. For the 
combined CX-4945 + TMZ therapy (Figure S2C), CX-4945 was administered every day whereas TMZ 
(60 mg/Kg) was dissolved in 10% DMSO in saline solution (0.9% NaCl) prepared as described in [5]. 
CX-4945 therapy was given until the end point of animal survival, when animals were euthanized 
because of welfare parameters. For this, animals were euthanized by cervical dislocation, the brain 
was removed and tumour resected. Samples were stored in liquid nitrogen until further processing 
for CK2 activity analysis.  
Regarding metronomic (every 6 days) administration protocol, eight doses of CX-4945 (150 
mg/Kg; 75 mg/kg at 8 h and 75 mg/kg at 16 h) were administered to CX-4945 treated group (Figure 
S2D), eight doses of TMZ (60mg/Kg at 12 h) were administered to TMZ treated group (Figure S2E) 
and eight doses of CX-4945 (150 mg/Kg75 mg/kg at 8 h, and 75 mg/kg at 16 h) plus TMZ (60 mg/Kg 
at 12 h) were administered to CX and TMZ combined therapy group (Figure S2F). Control mice 
received TMZ and CX-4945 vehicles. In all cases, the maximum cumulative dose administered of  
CX-4945 was 1200 mg/Kg and of TMZ, 480 mg/kg.  
All treatments were administered using an oral gavage and the administration volume for 
CX-4945 and TMZ was the same that has been used in our group for the TMZ administration (10 
µL/g weight animal) [5].  
4.8. CK2 Activity Assay 
CK2 activity was measured in 1–2 µg of lysate proteins (total protein extract of cell lysates) and 
5–10 µg (total protein extract of brain mice samples), previously incubated 10 min at 30 °C with 0.1 
mM CK2-tide (specific CK2 substrate peptide), by means of radioactive assays with gamma-33P 
ATP, in the presence of phosphorylation reaction mixture as described in [34].  
4.9. MRI Acquisition 
Magnetic resonance studies were carried out at the joint NMR facility of UAB and CIBER-BBN, 
Unit 25 of NANBIOSIS, with a 7T horizontal magnet (BioSpec 70/30, Bruker BioSpin, Ettlingen, 
Germany). GL261 tumour-bearing mice were screened by acquiring high resolution coronal T2W 
images (TR/TEeff = 4200/36 ms) using Rapid Acquisition with Relaxation Enhancement (RARE) 
sequence to detect brain tumour presence and monitor its evolution stage. The acquisition 
parameters were as follows: turbo factor, 8; field of view (FOV), 19.2 × 19.2 mm; matrix, 256 × 256  
(75 × 75 µm/pixel); number of slices, 10; slice thickness (ST), 0.5 mm; inter-ST, 0.6 mm; number of 
averages (NA), 4; total acquisition time (TAT), 6 min and 43 s.  
4.10. Tissue Homogenization and Protein Extraction/Western Blot Analysis 
Detailed information of the experimental procedures can be found in the Supplementary 
Materials file. 
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4.11. Statistical Analysis  
Variance homogeneity was assessed with the Levene’s test. A two-tailed Student’s t-test for 
independent measurements was used for comparisons, for samples of equal or different variances 
(depending on the Levene’s test result). Dixon’s and Grubb’s tests were used to detect outliers. The 
global evolution of tumour growth curves or body weight control was evaluated with the 
UNIANOVA test. Comparisons of survival rates were performed with the Log-Rank test. The 
significance level for all tests was p < 0.05. 
5. Conclusions 
CX-4945 has a noticeable effect in decreasing GL261 GBM cell viability and CK2 activity in 
vitro. Additionally, CK2 activity analysis confirmed that CX-4945 reached the target tissue in vivo. 
Notable differences in mice outcome were obtained with CX-4945 every day/alternated days (alone 
or combined with 3 cycles of TMZ), in comparison with metronomic administration of CX-4945 
and/or TMZ, the highest survival rates being obtained with the metronomic combining TMZ + 
CX-4945 every 6 days. 
An appealing explanation for this fact would be related with the immune system role in tumour 
response and the possible impairment of cytotoxic T-cell maturation cycle due to continued 
administration of CX-4945, which was overcome by the 6-day schedule metronomic administration. 
Accordingly, due care should be exercised when treating immunocompetent mice harbouring 
preclinical tumours with CX-4945 to ensure optimal results. 
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Abbreviation 
APG Apigenin 
CK2 Protein Kinase CK2 
CSCs Cancer stem cells 
CX-4945 5-(3-Chlorophenylamino)benzo[c][2,6] naphthyridine-8-carboxylic acid 
CPA Cyclophosphamide 
DC50 Half maximal cell death concentration 
DMSO Dimethyl sulfoxide 
EC50 Half maximal effective concentration,  
GABRMN Grup d’Aplicacions Biomèdiques de la RMN 
GBM Glioblastoma 
IC50 Half maximal inhibitory concentration 
iCK2 
JAK 
MGMT 
Protein Kinase CK2 inhibitors 
Janus kinase 
O(6)-methylguanine-DNA methyltransferase  
MTD Maximum tolerated dose 
p.i. Post-inoculation 
PIM-1 
STAT 3 
Proviral Integration of Moloney virus 1 
Signal transducer and activator of transcription 3 
TBB 4,5,6,7-Tetrabromobenzotriazole 
TDB Tetrabromodeoxyribofuranosyl-benzimidazole 
TMZ Temozolomide 
WB Western blot. 
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